

Resource Summary Report

Generated by [nidm-terms](#) on Jul 30, 2026

German Cancer Research Center

RRID:SCR_012942

Type: Tool

Proper Citation

German Cancer Research Center (RRID:SCR_012942)

Resource Information

URL: <http://www.dkfz.de/index.html>

Proper Citation: German Cancer Research Center (RRID:SCR_012942)

Description: Biomedical research institute in Germany that investigates the mechanisms of cancer and works to identify cancer risk factors. They provide the foundations for developing novel approaches in the prevention, diagnosis, and treatment of cancer and are a member of the Helmholtz Association of National Research Centers. Professor Harald zur Hausen was awarded the Nobel Prize for Medicine for his outstanding scientific contribution to the study of human papillomaviruses (HPV). In addition, the staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. The Center is funded by the German Federal Ministry of Education and Research (90%) and the State of Baden-Württemberg (10%).

Abbreviations: DKFZ

Synonyms: Deutsches Krebsforschungszentrum

Resource Type: institution

Related Condition: Cancer

Resource Name: German Cancer Research Center

Resource ID: SCR_012942

Alternate IDs: grid.7497.d, Wikidata: Q449325, ISNI: 0000 0004 0492 0584, nlx_36666, Crossref funder ID: 100008658

Alternate URLs: <https://ror.org/04cdgtt98>

Record Creation Time: 20220129T080313+0000

Record Last Update: 20260725T190740+0000

Ratings and Alerts

No rating or validation information has been found for German Cancer Research Center.

No alerts have been found for German Cancer Research Center.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Genovesi LA, et al. (2021) Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma. *Genome medicine*, 13(1), 103.

Cardoso F, et al. (2020) A multi-stakeholder approach in optimising patients' needs in the benefit assessment process of new metastatic breast cancer treatments. *Breast (Edinburgh, Scotland)*, 52, 78.

Algara López M, et al. (2020) OPTimizing Irradiation through Molecular Assessment of Lymph node (OPTIMAL): a randomized open label trial. *Radiation oncology (London, England)*, 15(1), 229.

Hörhold F, et al. (2020) Reprogramming of macrophages employing gene regulatory and metabolic network models. *PLoS computational biology*, 16(2), e1007657.

Wibberg D, et al. (2019) The de.NBI / ELIXIR-DE training platform - Bioinformatics training in Germany and across Europe within ELIXIR. *F1000Research*, 8.

Al Chiblak M, et al. (2019) DUF3669, a "domain of unknown function" within ZNF746 and ZNF777, oligomerizes and contributes to transcriptional repression. *BMC molecular and cell biology*, 20(1), 60.

Moldrich RX, et al. (2008) Transmembrane protein 50b (C21orf4), a candidate for Down syndrome neurophenotypes, encodes an intracellular membrane protein expressed in the rodent brain. *Neuroscience*, 154(4), 1255.